Biosergen’s groundbreaking antifugal drug BSG005 is granted Orphan Drug status in the United States
Sunday, June 27, 2021: Biosergen AB (“Biosergen” or the “Company”) today announced that the United States Food and Drug Administration (the “FDA”) has granted BSG005, the Company’s groundbreaking antifungal drug of the polyene macrolide class, Orphan Drug status in the United States. Orphan Drug status confers a number of important advantages including an expedited regulatory path and prolonged market exclusivity.Biosergen’s CEO Peder M. Andersen comments: “This is an important milestone for BSG005 and Biosergen. In addition to increasing the commercial value of the project the orphan